Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Cardiomyocyte-enriched protein CIP protects against pathophysiological stresses and regulates cardiac homeostasis
Zhan-Peng Huang, … , William T. Pu, Da-Zhi Wang
Zhan-Peng Huang, … , William T. Pu, Da-Zhi Wang
Published October 5, 2015
Citation Information: J Clin Invest. 2015;125(11):4122-4134. https://doi.org/10.1172/JCI82423.
View: Text | PDF
Research Article Cardiology

Cardiomyocyte-enriched protein CIP protects against pathophysiological stresses and regulates cardiac homeostasis

  • Text
  • PDF
Abstract

Cardiomyopathy is a common human disorder that is characterized by contractile dysfunction and cardiac remodeling. Genetic mutations and altered expression of genes encoding many signaling molecules and contractile proteins are associated with cardiomyopathy; however, how cardiomyocytes sense pathophysiological stresses in order to then modulate cardiac remodeling remains poorly understood. Here, we have described a regulator in the heart that harmonizes the progression of cardiac hypertrophy and dilation. We determined that expression of the myocyte-enriched protein cardiac ISL1-interacting protein (CIP, also known as MLIP) is reduced in patients with dilated cardiomyopathy. As CIP is highly conserved between human and mouse, we evaluated the effects of CIP deficiency on cardiac remodeling in mice. Deletion of the CIP-encoding gene accelerated progress from hypertrophy to heart failure in several cardiomyopathy models. Conversely, transgenic and AAV-mediated CIP overexpression prevented pathologic remodeling and preserved cardiac function. CIP deficiency combined with lamin A/C deletion resulted in severe dilated cardiomyopathy and cardiac dysfunction in the absence of stress. Transcriptome analyses of CIP-deficient hearts revealed that the p53- and FOXO1-mediated gene networks related to homeostasis are disturbed upon pressure overload stress. Moreover, FOXO1 overexpression suppressed stress-induced cardiomyocyte hypertrophy in CIP-deficient cardiomyocytes. Our studies identify CIP as a key regulator of cardiomyopathy that has potential as a therapeutic target to attenuate heart failure progression.

Authors

Zhan-Peng Huang, Masaharu Kataoka, Jinghai Chen, Gengze Wu, Jian Ding, Mao Nie, Zhiqiang Lin, Jianming Liu, Xiaoyun Hu, Lixin Ma, Bin Zhou, Hiroko Wakimoto, Chunyu Zeng, Jan Kyselovic, Zhong-Liang Deng, Christine E. Seidman, J.G. Seidman, William T. Pu, Da-Zhi Wang

×

Figure 5

Gain of function of CIP protects the heart from mal-remodeling.

Options: View larger image (or click on image) Download as PowerPoint
Gain of function of CIP protects the heart from mal-remodeling.
(A) LV p...
(A) LV posterior wall thickness at end-diastole, LV internal dimension at end-diastole, and FS of TAC- or sham-operated (4 weeks) CIP-OE and control mice. (B) The ventricle weight/body weight (Vw/Bw) ratio of CIP-OE and control hearts 4 weeks after TAC or sham operation. (C) Wheat germ agglutinin staining and cardiomyocyte cross-sectional area quantification of indicated hearts. Scale bar: 50 μm. (D) Fast green and Sirius red staining of CIP-OE and control hearts 4 weeks after TAC or sham operation. Scale bar: 1.5 mm. (E) qRT-PCR detection of the expression of hypertrophy marker genes in TAC- or sham-operated (4 weeks) CIP-OE and control hearts. n = 4–5 for each group. (F) Gross heart morphology and H&E staining of CIP-OE and control hearts 10 weeks after TAC or sham operation. Scale bar: 1.6 mm. (G) Dynamics of LV dimension and cardiac function 4 and 10 weeks after TAC or sham operation in CIP-OE and control mice. n = 8–15 for each group. (H) H&E staining of 4-week-old CnA-Tg and control mice injected with AAV9-CIP or control virus (AAV9-GFP). Scale bar: 1.5 mm. (I) Ventricle weight/body weight ratio of CnA-Tg and control mice injected with AAV9-CIP or control virus. (J) qRT-PCR detection of the expression of hypertrophy marker genes and CIP in CnA-Tg and control hearts with AAV9-CIP virus or control virus. n = 5–8 for each group. *P < 0.05, **P < 0.01, 1-way ANOVA with post-hoc Tukey’s test.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts